Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $55.6 million.

  • Anika Therapeutics' Cash & Equivalents fell 7.02% to $58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year decrease of 7.02%. This contributed to the annual value of $55.6 million for FY2024, which is 19.07% down from last year.
  • Latest data reveals that Anika Therapeutics reported Cash & Equivalents of $55.6 million as of FY2024, which was down 19.07% from $68.7 million recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Cash & Equivalents peaked at $95.8 million during FY2020, and registered a low of $55.6 million during FY2024.
  • Over the past 3 years, Anika Therapeutics' median Cash & Equivalents value was $68.7 million (recorded in 2023), while the average stood at $70.2 million.
  • Data for Anika Therapeutics' Cash & Equivalents shows a maximum YoY slumped of 39.15% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Anika Therapeutics' Cash & Equivalents stood at $95.8 million in 2020, then declined by 1.49% to $94.4 million in 2021, then decreased by 8.54% to $86.3 million in 2022, then decreased by 20.37% to $68.7 million in 2023, then decreased by 19.07% to $55.6 million in 2024.